- Oral presentation
- Open Access
- Published:
Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
Pediatric Rheumatology volume 13, Article number: O38 (2015)
Background
Canakinumab (CAN) is indicated for the treatment of cryopyrin-associated periodic syndrome (CAPS) in patients ≥2 years of age [1]. However, information on the pharmacokinetics (PK) of CAN in patients <2 years of age is not available. Here, we present preliminary PK data from a phase III study in CAPS patients.
Objectives
To assess the efficacy of CAN with respect to the treatment response in CAPS patients ≤4 years of age and to evaluate PK and pharmacodynamics (PD) profiling of CAN.
Methods
CAN-naïve patients with confirmed CAPS aged 44 days to 4 years received open-label CAN 2 mg/kg every 8 weeks for 56 weeks. For NOMID patients, an initial dose of 4 mg/kg was administered. Patients who did not achieve complete response following CAN injection, or experienced a flare before the next planned administration, were eligible for dose up-titration with possible maintenance and step wise up-titration regimens of 4, 6, or 8 mg/kg s.c.
Results
Seventeen patients, 6 patients <24 months old (44 days to 14 months; mean age = 7 months), were enrolled and administered body weight-based (2 mg/kg up to 12 mg/kg) doses of CAN s.c. every 8 weeks, with the exception of one patient who received doses of 4-6 mg/kg once weekly. Of the 6 patients <24 months old, 5 were dosed with 2 mg/kg at each dose while 1 NOMID patient started with 4 mg/kg and up-titrated to 8 mg/kg at last dose. Sixteen patients achieved a complete response, with 7 patients requiring dose escalation to achieve and/or maintain their responses. Mean dose-normalized CAN trough concentrations at steady-state in the patients <24 months old were similar across the 6 patients from 44 days to 15 months, while the range of exposures as represented by the dose normalized trough levels overlapped with the remaining 11 study patients >2 years old who received CAN doses ranging from 2 mg/kg up to12 mg/kg.
Conclusions
Canakinumab is an effective treatment for patients with CAPS aged as young as 44 days old. The preliminary PK results demonstrated that dose-normalized canakinumab exposure in patients <2 years old was similar to patients >2 years supporting the utilization of weight-based dosing in the CAPS infantile population.
References
ILARIS [summary of product characteristics]: 2014, Novartis Europharm Limited
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Kalabus, J., Brogan, P., Hofer, M. et al. Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS. Pediatr Rheumatol 13 (Suppl 1), O38 (2015). https://doi.org/10.1186/1546-0096-13-S1-O38
Published:
DOI: https://doi.org/10.1186/1546-0096-13-S1-O38
Keywords
- Effective Treatment
- Treatment Response
- Study Patient
- Initial Dose
- Dose Escalation